Medicine and Dentistry
Antithrombotic
100%
Circulating Tumor Cell
100%
Leukapheresis
77%
Diagnosis
71%
Plasma Exchange
62%
COVID-19
50%
Myeloproliferative Neoplasm
50%
Idiopathic Thrombocytopenic Purpura
50%
Antiphospholipid Syndrome
50%
Venous Thromboembolism
50%
Thrombotic Thrombocytopenic Purpura
50%
Coma
50%
Skin Defect
50%
Randomized Controlled Trial
50%
Systematic Review
50%
Immunocompromised Patient
50%
COVID-19 Vaccination
50%
Prostate Cancer
50%
Organoid
50%
Hematinic
50%
Purpura
50%
Hyperimmune Globulin
50%
Metastatic Melanoma
50%
Cell-Free DNA
50%
Lenalidomide
50%
Arm
50%
Myelodysplastic Syndrome
50%
Coronavirinae
40%
Platelet
35%
Neoplasm
27%
Observational Study
25%
Epileptic Seizure
25%
Granulocyte Colony Stimulating Factor
25%
Myelodysplastic Syndrome
25%
Thrombosis
23%
Absence
20%
Immunoglobulin
20%
Flow Cytometry
19%
Anticoagulation
16%
Recurrence Risk
16%
Direct Oral Anticoagulant
16%
Lupus Anticoagulant
14%
Antiphospholipid Antibody
14%
Immunoglobulin M
14%
Hypertensive Crisis
12%
Brain Imaging
12%
Blood Pressure
12%
Deterioration
12%
Critical Illness
12%
Von Willebrand Factor Cleaving Proteinase
12%
Immunology and Microbiology
Circulating Tumor Cell
100%
Leukapheresis
77%
ABO Blood Group System
50%
Severe Acute Respiratory Syndrome Coronavirus 2
50%
Blood Plasma
50%
Cold Agglutinin Disease
50%
Warm Autoimmune Hemolytic Anemia
50%
Neutralizing Antibody
50%
Daratumumab
50%
Lenalidomide
50%
Erythropoiesis-Stimulating Agent
50%
Organoid
50%
Immunoadsorption
50%
Kidney Transplantation
50%
Arm
50%
Antibody Mediated Rejection
50%
Autoimmune Hemolytic Anemia
37%
CD38
31%
Rituximab
31%
Intravenous Immunoglobulin
25%
Antibody Titer
25%
Transplant Procedure
25%
Granulocyte Colony-Stimulating Factor
25%
Prostate
18%
Titer
16%
COVID-19
16%
Monospecific Antibody
16%
Tumor Volume
16%
B Cell
16%
T Cell
12%
Tumor Cell
12%
Epithelial Cell Adhesion Molecule
12%
Autoantibodies
12%
Leukocyte
12%
Viral Clearance
8%
Independence
8%
Humoral Immunity
8%
Proinflammatory Cytokine
8%
Next Generation Sequencing
8%
T Cell Subset
6%
Monoclonal Antibody
6%
Plasma Cell
6%
T Cell Depletion
6%
DNA Sequence
6%
Secretion (Process)
6%
Cell Line
6%
Cell Activation
6%
Cell Proliferation
6%
Lactate Dehydrogenase Blood Level
5%
Gene Frequency
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ruxolitinib
100%
Neoplasm
100%
Disease
58%
Observational Study
50%
Lenalidomide
50%
Immunocompromised Patient
50%
Myelodysplastic Syndrome
50%
Randomized Controlled Trial
50%
Coronavirinae
50%
Hydroxycarbamide
50%
Polycythemia vera
50%
Arsphenamine
50%
Hyperimmune Globulin
50%
Metastatic Melanoma
50%
Myelofibrosis
50%
Prostate Cancer
50%
Granulocyte Colony Stimulating Factor
37%
Adverse Event
22%
Flow Cytometry
19%
Anemia
15%
Thrombocytopenia
14%
Absence
12%
Efficacy Study
12%
Immunoglobulin
11%
Syndrome
11%
Epithelial Cell Adhesion Molecule
11%
Remission
8%
Phase IV
8%
Lactate Dehydrogenase
7%
Biological Marker
7%
Aneuploidy
7%
Myeloproliferative Neoplasm
7%
Monoclonal Antibody
5%
SARS Coronavirus
5%
Cell DNA
5%
Malignant Neoplasm
5%
